BA
CYTK icon

BlackRock Advisors’s Cytokinetics CYTK Stock Holding History

BlackRock Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.5M Buy
123,763
+948
+0.8% +$10.1K ﹤0.01% 1647
2016
Q3 		$1.13M Buy
122,815
+1,115
+0.9% +$11.6K ﹤0.01% 1763
2016
Q2 		$1.16M Sell
121,700
-1,930
-2% -$15.8K ﹤0.01% 1698
2016
Q1 		$872K Buy
123,630
+1,502
+1% +$11K ﹤0.01% 1809
2015
Q4 		$1.28M Sell
122,128
-63,655
-34% -$624K ﹤0.01% 1603
2015
Q3 		$1.24M Buy
185,783
+11,187
+6% +$76.4K ﹤0.01% 1560
2015
Q2 		$1.17M Sell
174,596
-68,966
-28% -$452K ﹤0.01% 1557
2015
Q1 		$1.65M Sell
243,562
-2,306
-0.9% -$17.2K ﹤0.01% 1306
2014
Q4 		$1.97M Sell
245,868
-3,571
-1% -$15.3K ﹤0.01% 1205
2014
Q3 		$878K Buy
249,439
+1,573
+0.6% +$6.61K ﹤0.01% 1515
2014
Q2 		$1.19M Sell
247,866
-31,363
-11% -$191K ﹤0.01% 1397
2014
Q1 		$2.65M Sell
279,229
-7,330
-3% -$66.3K ﹤0.01% 1108
2013
Q4 		$1.86M Buy
286,559
+269,501
+1,580% +$1.77M ﹤0.01% 1214
2013
Q3 		$129K Buy
+17,058
New +$183K ﹤0.01% 2804

Other funds holding CYTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock Advisors's CYTK Position: Q4 2016 in Review

BlackRock Advisors increased its Cytokinetics (CYTK) stake by 0.77% in Q4 2016, buying an estimated $10.1K and bringing the position to 123,763 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1647.

BlackRock Advisors first reported a position in CYTK in Q3 2013 and has held it in 14 quarters since. The position peaked at $2.65M in Q1 2014. 101 funds tracked by Wall St. Rank hold CYTK as of Q4 2016.

  • BlackRock Advisors held 123,763 shares of Cytokinetics worth $1.5M as of Q4 2016.
  • BlackRock Advisors bought 948 Cytokinetics shares in Q4 2016, an estimated $10.1K.
  • Cytokinetics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1647 holding.
  • BlackRock Advisors first reported a position in Cytokinetics in Q3 2013 and has held it in 14 quarters since.
  • BlackRock Advisors's Cytokinetics position peaked at $2.65M in Q1 2014.
  • 101 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.